RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration

Return to Grants

Grant Award Details

Grant Number:

Human Stem Cell Use:
Award Value:

Grant Application Details

Application Title:

RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration

Public Abstract:
Therapeutic Candidate or Device

Retina pigment epithelial stem cell (RPESC)-derived RPE progeny at 4 weeks of differentiation (RPESC-RPE-4W)


Dry age-related macular degeneration (dry AMD).

Therapeutic Mechanism

Dry AMD involves loss of the RPE cells that support the overlying retina and vision. We transplant laboratory grown RPESC-RPE-4W cell to replace the RPE cells lost in dry AMD to restore vision.

Unmet Medical Need

Many people experience vision loss due to dry AMD and there is no current therapy to improve vision. Transplantation of RPESC-RPE-4W cells aims to restore vision that has been lost to dry AMD disease progression.

Project Objective

Phase 1/2a trial completed in California.

Major Proposed Activities

  • Clinical sites for the ongoing trial will be opened in California.
  • Manufacturing of RPESC-RPE-4W cell product in California.
Statement of Benefit to California:
Many Californians with vision loss due to dry AMD lack available vision-improving treatment option. Development of a treatment to improve vision lost to dry AMD will enable tasks of everyday living. to restore dry AMD patient ability to travel, work and play.